-
30 October 2024anemptytextllinePhysiogenex now delivers its novel rat model of IgA nephropathy (IgAN) to rapidly evaluate... -
3 March 2024anemptytextllineiLEADS BMS presents the effects of its novel FXR agonist in Physiogenex's ALD/MetALD hamster... -
30 January 2024anemptytextllineHepaRegenix publishes data on first in class MKK4 inhibitors demonstrating benefits in Physiogenex CCl4... -
4 December 2023anemptytextllineiLeads BMS publishes a new manuscript about its novel FXR agonist in Physiogenex's obese... -
23 November 2023anemptytextllinePhysiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity... -
6 November 2023anemptytextllinePhysiogenex will be presenting a novel obese NASH hamster model of MetALD (Metabolic Dysfunction-Associated... -
6 November 2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 7th IPF Summit to be... -
29 August 2023anemptytextllinePhysiogenex will be presenting a new NASH hamster study at the 10th Aging Research... -
17 June 2023anemptytextllinePhysiogenex will be presenting a new DIABETIC NASH HFpEF hamster study at the 83rd... -
30 May 2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 1st Type 2 diabetes &... -
11 May 2023anemptytextllinePhysiogenex will be attending Biomed Israël 2023 annual meeting in Tel Aviv, May 16... -
11 May 2023anemptytextllinePhysiogenex, a leading preclinical contract research organization specialized in metabolic diseases and complications, and... -
19 April 2023anemptytextllinePhysiogenex and its subsidiary company Cardiomedex will be presenting a new diabetic NASH HFpEF... -
28 March 2023anemptytextllinePhysiogenex, its subsidiary company Cardiomedex, and its partner CLEA Japan Inc., will be presenting... -
15 March 2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the NAFLD/NASH Keystone... -
6 March 2023anemptytextllinePhysiogenex is a proud sponsor of the Hanson Wade 5th CKD Summit to be... -
27 February 2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the Global NASH... -
18 January 2023anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the 2nd HFpEF... -
27 December 2022anemptytextllinePhysiogenex is delighted to be awarded ISO 9001:2015, a globally recognized certification of quality... -
29 November 2022anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the 20th World... -
22 November 2022anemptytextllinePhysiogenex will be presenting its innovative obese MetALD hamster model at the 7th Obesity...
-
8 November 2022anemptytextllinePhysiogenex will be presenting its innovative obese NASH hamster model at the AFDD (AntiFibrotic... -
28 October 2022anemptytextllinePhysiogenex will be presenting 2 novel studies in its innovative obese NASH hamster model... -
14 October 2022anemptytextllinePhysiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH... -
27 September 2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
15 September 2022anemptytextllinePhysiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD... -
30 August 2022anemptytextllinePhysiogenex will be presenting a new DIO mouse study at the 9th Aging Research...
-
25 August 2022anemptytextllinePhysiogenex and its subsidiary company Cardiomedex will be presenting their original preclinical models during... -
21 June 2022anemptytextllinePhysiogenex will be exhibiting at booth#51 and presenting a new DIO-NASH mouse study (abstract#258)... -
10 June 2022anemptytextllinePhysiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH... -
2 June 2022anemptytextllinePhysiogenex will be presenting a new DIO-NASH mouse study at the 82nd Scientific Sessions... -
23 May 2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of clinical benchmarks in its innovative obese... -
13 May 2022anemptytextllinePhysiogenex will be presenting its two obese/type 2 diabetic rat models of nephropathy at... -
3 May 2022anemptytextllinePhysiogenex will be presenting the effects of SARS-CoV-2 infection on dyslipidemia and NASH in... -
19 April 2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
4 April 2022anemptytextllinePhysiogenex will be presenting a poster at the Keystone Symposia - Lessons from the... -
29 March 2022anemptytextllinePhysiogenex will be presenting an e-Poster at the 31st conference of the Asian Pacific... -
17 March 2022anemptytextllinePhysiogenex invites you to attend its new webinar presented by our expert Dr. François Briand... -
19 January 2022anemptytextllineFrançois Briand, Director of Research and Business Development at Physiogenex, will be giving a... -
1 January 2022anemptytextllinePhysiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in... -
24 November 2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
7 September 2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
26 August 2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type... -
3 June 2021anemptytextllinePhysiogenex, a preclinical Contract Research Organization providing CRO services for developing drugs targeting obesity/type...
CONTACT US FOR MORE INFORMATION